Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Publications
2 shownIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously un...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 10,066
- Institution
- Hadassah Medical Center
External Links
Identifiers
- ORCID
- 0000-0003-1703-8008
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.